- Bedside-to-Laboratory Translational Work Identifies Novel Tumor-Specific AntigenMay 01, 2008 | John C. Byrd, MD
Chronic lymphocytic leukemia (CLL) is associated with profound suppression of the humoral, innate, and cellular components of the immune system. CLL cells are transformed B lymphocytes but lack classic co-stimulatory molecules typically present on normal B cells.
- Clinical Penetrance of HFE Hereditary Hemochromatosis, Serum Ferritin Levels, and Screening Implications: Can We Iron This Out?May 01, 2008 | Michael Linenberger, MD
Since the discovery of the homozygous C282Y mutation of the HFE gene as the major cause of hereditary iron overload in Caucasians of Northern European descent, numerous studies have attempted to define the risk of iron-overload-related disease and a practical rationale for screening.
- Combination Proteasome Inhibitor TherapyMay 01, 2008 | Kenneth C. Anderson, MD
The proteasome inhibitor bortezomib, which primarily targets the chymotryptic-like (CT-L) proteolytic activity of the proteasome, is an effective therapy for patients with relapsed refractory multiple myeloma (MM) and is superior to high-dose dexamethasone therapy for relapsed MM.
- GVHD Has Proteomics Come of Age?May 01, 2008 | Gérard Socié, MD, PhD
Although graft-versus-host disease (GVHD) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT), its current diagnosis mainly depends on clinical manifestations and invasive biopsies. Early diagnosis of GVHD, preferably based on unbiased laboratory screening tools, may increase the safety of allogeneic HSCT and thus further broaden its application to even larger patient populations.
- Performance-Enhancing DrugsMay 01, 2008 | Nelson Chao, MD, MBA
Did Mark McGwire use it or not? We all have our opinions, but we do know that his wife used it. The drug is human growth hormone. Human growth hormone (HGH) is known to improve muscle strength and has been claimed as an anti-aging agent because it can increase lean body mass and bone mineral density, although there are limited data to support this claim.
- Role of miR223 in MyelopoiesisMay 01, 2008 | Diane Krause, MD, PhD | Stephanie Halene, MD
New avenues of discovery have opened over the last decade with the discovery of microRNAs. MiRNAs are small RNAs of approximately 22 nucleotide length, which are transcribed from genomic DNA like messenger RNAs (mRNAs) but do not encode proteins. Their main function is that of gene regulation by targeting specific sequences in the 3'-untranslated region of mRNAs.